The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index; 70 of the 140 sources its claims cite were checked for support.
Nitazenes: The Emergence of a Potent Synthetic Opioid Threat
Open accessAbstract
The global unregulated drug supply faces a critical challenge with the emergence of nitazenes, a class of novel synthetic opioids (NSOs) structurally distinct from fentanyl and associated with extreme potency and high risk of fatal overdose. First synthesised in the late 1950s, etonitazene was a target of preclinical research in rats and rhesus monkeys, but it never reached clinical trials due to an unfavourable balance between therapeutic and toxic effects. Nitazenes' consistent reappearance began in 2019 with isotonitazene, followed by a rapid proliferation of analogues worldwide, many reported to be hundreds to thousands of times more potent than morphine and, in some cases, stronger than fentanyl. This rise is fuelled by their ease of synthesis, low production costs, and evasion of regulatory controls. Nitazenes are frequently mis-sold as counterfeit medications or adulterated into other drugs, resulting in unintentional exposure and overdose, particularly among opioid-naïve users. The primary cause of death is severe and prolonged respiratory depression. Analytical challenges are significant, as traditional screening methods are ineffective, and the low concentration in biological samples requires expensive and highly sensitive liquid chromatography mass spectrometry techniques. This perspective paper highlights critical gaps in detection, clinical management, and regulatory readiness for nitazenes. Urgent efforts are needed to improve surveillance, develop robust analytical methodologies, provide clinical guidance to nitazene intoxications, and strengthen international policy to curb their proliferation.
Overview
CoChat Summary
TL;DR
This perspective paper reviews the emergence of nitazenes, a class of highly potent 2-benzylbenzimidazole synthetic opioids distinct from fentanyl, and argues they pose an escalating global overdose threat. It highlights critical gaps in detection, clinical management, and regulatory readiness, calling for improved surveillance, analytical methods, naloxone guidance, and international control.
Key findings
- Nitazenes were first synthesised in the late 1950s but never approved clinically; isotonitazene emerged in 2019, followed by dozens of analogues, with 12 nitazenes scheduled by the UN Commission on Narcotic Drugs and around 30 reported through the UNODC Early Warning Advisory System.
- Potency varies widely: etonitazene is reported as 100–1000 times more potent than morphine and 10–20 times more potent than fentanyl; isotonitazene ~500 times morphine; metonitazene equipotent to fentanyl and ~100 times morphine; protonitazene ~2 times fentanyl and ~200 times morphine. The metabolite N-desethyl isotonitazene is more potent than its parent and can cause longer-lasting respiratory depression.
- In Tennessee, 52 nitazene-involved fatal overdoses occurred from 2019 to 2021, rising fourfold from 10 cases in 2020 to 42 in 2021, with metonitazene accounting for 85.7% of these deaths in 2021. In Europe, 21 of 27 EU Member States plus Norway reported nitazenes since 2019; 22 nitazenes have been detected in Europe, and nitazene powder seized in 2023 tripled to 10 kg compared with 2022.
- Traditional immunoassays and fentanyl test strips are largely ineffective for nitazenes; detection often requires liquid chromatography–mass spectrometry because concentrations in biological samples are typically sub-ng/mL or sub-pmol/mL. Naloxone remains effective, but higher, repeated, or continuous doses may be needed due to high potency, slow MOR dissociation, and prolonged active metabolites.
Methods
- Perspective paper that synthesises published literature, toxicology reports, surveillance data, and regulatory sources; no primary experimental data are presented.
- Covers global epidemiology, pharmacology and toxicity, analytical challenges, and strategic responses, including detection, clinical management, harm reduction, and policy.
- No systematic review protocol, meta-analysis, or primary sample collection is described.
Limitations
- The paper does not present a formal limitations section; it states that information on nitazene pharmacology, toxicology, and harms remains limited, and that studies on monointoxications, human pharmacokinetics, and non-rodent species are lacking.
- Evident from the text: as a perspective/narrative review, evidence selection is not systematic, and many quantitative claims rely on cited reports and surveillance systems that may underestimate nitazene-related deaths and intoxications.
- The paper notes that detection is constrained by inaccessible high-resolution instruments, limited reference standards, and underreporting, especially in low-income countries.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Nitazene core structure and 12 analogues under the UNODC International Drug Control Conventions [17]. Marvin was used for drawing the chemical structures: Marvin 17.21.0, Chemaxon (https://www.chemaxon.com).](https://figures.cochat.ai/paper-figures/e3dcface92924b1888ee0ffb859d55dd/nitazenes-the-emergence-of-a-potent-synthetic-opioid-threat-figure-2.jpg)
![Figure 3 Top new opioids seized (a) by number of seizures (749 seizures) and (b) by quantity seized (16.6 kg seized) reported to the EU Early Warning System, 2022. Adapted from EUDA [26].](https://figures.cochat.ai/paper-figures/d337e16bc0f14289b9ac70f1a40833ad/nitazenes-the-emergence-of-a-potent-synthetic-opioid-threat-figure-3.jpg)
Verification
Claims the paper makes
35 Valid · 9 Not valid · 19 Not checked · 15 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“in clinical settings, naloxone remains an effective antidote for nitazene intoxication, consistent with its efficacy against other potent opioids.”
§ Nitazenes: The Emergence of a Potent Synthetic Opioid Threat > 3. Pharmacological Profile and Toxicity of Nitazenes
What the sources say
- Partly supportedcites [11] Berger, 2025, Naloxone Dosing and Hospitalization for Nitazene Overdose: A Scoping Review, J. Med. Toxicol. sourceExperimental — accuracy not yet measured
The Naloxone Dosing section reports nitazene overdoses reversed with naloxone, supporting its clinical use as an antidote. But it also reports four deaths among 17 cases, and the Discussion says evidence is limited and effective dosing remains uncertain. The copy does not establish a comparison of naloxone’s efficacy against nitazenes and other potent opioids. (LLM, conf=0.82)
- Partly supportedcites [42] Amaducci, 2023, Naloxone Use in Novel Potent Opioid and Fentanyl Overdoses in Emergency Department Patients, JAMA Netw. Open sourceExperimental — accuracy not yet measured
The Results report reversal of symptoms after naloxone in patients with isotonitazene and N-piperidinyl etonitazene overdose, supporting its clinical effectiveness in several nitazene cases. But one patient with metonitazene died despite three naloxone doses, and the Conclusions describe the findings as preliminary. The unqualified claim that naloxone is effective for nitazene intoxication overstates this small cohort's findings; page numbers are not available in the supplied passages. (LLM, conf=0.86)
- Partly supportedcites [43] Alhosan, 2025, Slow Dissociation Kinetics of Fentanyls and Nitazenes Correlates with Reduced Sensitivity to Naloxone Reversal at the μ-Opioid Receptor, Br. J. Pharmacol. sourceExperimental — accuracy not yet measured
The Introduction (Naloxone antagonism) identifies naloxone as an opioid-overdose antidote and reports clinical cases involving nitazenes. The Conclusions say reversal may require higher doses than for heroin, a qualification missing from the claim. The paper's own reversal experiments were in vitro, not clinical; page numbers were not provided in our copy. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Many nitazenes demonstrate MOR binding affinities comparable to, or exceeding, those of morphine and fentanyl [29,30,31,32,33].”
§ Nitazenes: The Emergence of a Potent Synthetic Opioid Threat > 3. Pharmacological Profile and Toxicity of Nitazenes
What the sources say
- Supportedcites [29] Malcolm, 2023, Mu-Opioid Receptor Selective Superagonists Produce Prolonged Respiratory Depression, iScience source
The Results section (‘Members of the nitazene family are potent superagonists at MOR’; page unavailable) reports radioligand-binding assays in which the tested nitazenes had greater MOR affinity than conventional opioids. It specifically reports approximately tenfold greater affinity for isotonitazene than fentanyl, and Figure 2E includes morphine in the binding-affinity comparison. (LLM, conf=0.91)
- Partly supportedcites [30] Vandeputte, 2024, Characterization of Novel Nitazene Recreational Drugs: Insights into Their Risk Potential from in Vitro µ-Opioid Receptor Assays and in Vivo Behavioral Studies in Mice, Pharmacol. Res. sourceExperimental — accuracy not yet measured
The Results (page unavailable) report nanomolar MOR binding affinities for all tested nitazenes and say that fentanyl and morphine were among the reference opioids measured. The available binding passages do not establish that many nitazenes have affinities comparable to or greater than both drugs. The Results do compare some nitazenes with fentanyl on functional potency, but potency is not binding affinity. (LLM, conf=0.78)
- Partly supportedcites [31] Tsai, 2024, In Vitro Functional Profiling of Fentanyl and Nitazene Analogs at the μ-Opioid Receptor Reveals High Efficacy for Gi Protein Signaling, ACS Chem. Neurosci. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports that most tested nitazenes had higher model-derived pKA values than the fentanyls, supporting a comparison of MOR functional affinity. The Results section on functional bias (page unavailable) describes morphine as having lower functional affinity than DAMGO, but does not directly compare its binding affinity with the nitazenes. The paper’s functional-affinity and potency findings therefore do not fully establish the claimed binding-affinity comparison with both morphine and fentanyl. (LLM, conf=0.84)
- Partly supportedcites [32] Walton, 2024, In Vitro Structure–Activity Relationships and Forensic Case Series of Emerging 2-Benzylbenzimidazole ‘Nitazene’ Opioids, Arch. Toxicol. sourceExperimental — accuracy not yet measured
The Results (Pharmacological characterization; page not provided) report that several nitazenes had greater MOR functional potency than morphine and fentanyl in two activation assays. The paper reports EC50-based potency and efficacy, not MOR binding affinity, so it does not establish the claim specifically about binding affinities. (LLM, conf=0.85)
- Partly supportedcites [33] Magny, R., Schiestel, T., M’Rad, A., Lefrère, B., Raphalen, J.H., Ledochowski, S., Labat, L., Mégarbane, B., and Houzé, P. (2025). Comparison of the Metabolic Profiles Associated with Protonitazene and Protonitazepyne in Two Severe Poisonings. Metabolites, 15. sourceExperimental — accuracy not yet measured
The Introduction describes nitazenes as having high MOR affinity and says etonitazene is more potent than morphine. The Discussion describes nitazenes as about ten times more potent than fentanyl. Neither section compares their MOR binding affinities with those of morphine or fentanyl; potency is not the same measure as binding affinity. (LLM, conf=0.84)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“while isotonitazene is estimated at ~500 times the potency of morphine [12,34].”
§ Nitazenes: The Emergence of a Potent Synthetic Opioid Threat > 3. Pharmacological Profile and Toxicity of Nitazenes
What the sources say
- Partly supportedcites [12] Stangeland, 2025, Nitazenes: Review of Comparative Pharmacology and Antagonist Action, Clin. Toxicol. sourceExperimental — accuracy not yet measured
The In vitro and animal studies section reports that isotonitazene has high mu-opioid receptor potency and is approximately 125 times as potent as fentanyl. Neither that section nor the comparative-potency passages give a 500-fold estimate relative to morphine, so the specific figure is unsupported by our copy. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [34] Tomiyama, 2025, The Synthetic Opioid Isotonitazene Induces Locomotor Activity and Reward Effects through Modulation of the Central Dopaminergic System in Mice, Toxicol. Appl. Pharmacol. source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Liquid chromatography–mass spectrometry-based techniques, such as liquid chromatography–triple-quadrupole mass spectrometry and liquid chromatography–time-of-flight mass spectrometry, have become the preferred approaches for screening and quantification in forensic and toxicological laboratories.”
§ Nitazenes: The Emergence of a Potent Synthetic Opioid Threat > 4. Analytical Challenges in Forensic and Toxicological Investigations
What the sources say
- Not checked — no full text of the sourcecites [52] Hardwick, 2024, Structural Characterization of Nitazene Analogs Using Electron Ionization-Mass Spectrometry (EI-MS), Forensic Chem. source
- Not checked — no full text of the sourcecites [53] Hardwick, E.K., and Davidson, J.T. (2025). Structural Characterization of Nitazene Analogs Using Electrospray Ionization–Tandem Mass Spectrometry (ESI–MS/MS). Drug Test. Anal. source
- Not checked — no full text of the sourcecites [54] Ververi, C., Galletto, M., Massano, M., Alladio, E., Vincenti, M., and Salomone, A. (2024). Method Development for the Quantification of Nine Nitazene Analogs and Brorphine in Dried Blood Spots Utilizing Liquid Chromatography—Tandem Mass Spectrometry. J. Pharm. Biomed. Anal., 241. source
- Not checked — no full text of the sourcecites [55] Wachełko, O., Tusiewicz, K., Szpot, P., and Zawadzki, M. (2025). The UHPLC-MS/MS Method for the Determination of 26 Synthetic Benzimidazole Opioids (Nitazene Analogs) with Isomers Separation. J. Pharm. Biomed. Anal., 260. source
- Partly supportedcites [56] Lucic, 2023, High-Throughput Quantification of Emerging “Nitazene” Benzimidazole Opioid Analogs by Microextraction and UHPLC-MS-MS, J. Anal. Toxicol. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, older gas chromatography–mass spectrometry methods also frequently lack the necessary sensitivity for nitazenes, often missing them in casework [50,51,52].”
§ Nitazenes: The Emergence of a Potent Synthetic Opioid Threat > 4. Analytical Challenges in Forensic and Toxicological Investigations
What the sources say
- Partly supportedcites [50] Keller, E.L., Peake, B., Simpson, B.S., White, J.M., and Gerber, C. (2025). Comprehensive Method to Detect Nitazene Analogues and Xylazine in Wastewater. Environ. Sci. Pollut. Res. sourceExperimental — accuracy not yet measured
The Results and discussion section says gas chromatography may lack the sensitivity or selectivity needed to detect nitazenes in wastewater. It does not describe older GC–MS methods, establish that this happens frequently, or report nitazenes being missed in forensic casework. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [51] Phelps, 2025, Development and Validation of a Combined Selected Ion Monitoring-Scan GC-EI-MS Method for Nitazene Analogs, J. Forensic Sci. source
- Not checked — no full text of the sourcecites [52] Hardwick, 2024, Structural Characterization of Nitazene Analogs Using Electron Ionization-Mass Spectrometry (EI-MS), Forensic Chem. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 12 with their cited sources checked
Create a free account to see all 78 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 41
- Probably not a substantial claim. 11
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“It has been described as 1000-fold more potent than morphine is at the same receptor [23].”
From Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs (2026) · cites this paper as [23]
Citations
Cites
Jamal, A., Park-Lee, E., Birdsey, J., West, A., Cornelius, M., Cooper, M. R., Cowan, H., Wang, J., Sawdey, M. D., Cullen, K. A., et al. (2024) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7341a2 · Cited by 258 · cited 1×
“Similar educational initiatives have been successfully implemented in tobacco prevention programs, demonstrating promising results [69].”
Nitazenes—Heralding a Second Wave for the UK Drug-Related Death Crisis?
Holland, A., Copeland, C. S., Shorter, G. W., Connolly, D. J., Wiseman, A., Mooney, J., Fenton, K., & Harris, M. (2024) · The Lancet Public Health · doi:10.1016/s2468-2667(24)00001-x · Cited by 86 · cited 2×
“The UK National Crime Agency reported 54 nitazene-related deaths within six months, a scenario likely to be an underestimation [19].”
Naloxone Use in Novel Potent Opioid and Fentanyl Overdoses in Emergency Department Patients
Amaducci, A., Aldy, K., Campleman, S. L., Li, S., Meyn, A., Abston, S., Culbreth, R. E., Krotulski, A., Logan, B., Wax, P., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.31264 · Cited by 84 · cited 2×
“Furthermore, the rapid metabolism of nitazenes and the involvement of polymorphic CYP enzymes may influence individual susceptibility to intoxication and addiction, while also complicating toxicological and forensic analysis [6,12,35,42].”
Old Drugs and New Challenges: A Narrative Review of Nitazenes
Pergolizzi Jr, J., Raffa, R., LeQuang, J. A. K., Breve, F., & Varrassi, G. (2023) · Cureus · doi:10.7759/cureus.40736 · Cited by 81
De Vrieze, L. M., Walton, S. E., Pottie, E., Papsun, D., Logan, B. K., Krotulski, A. J., Stove, C. P., & Vandeputte, M. M. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03774-7 · Cited by 58 · cited 1×
“This combination of high potency and MOR superagonism can suggest the risk of prolonged hypoventilation and potential hypoxic injury [29,32,35].”
Non-Fentanyl New Synthetic Opioids—An Update
Zawilska, J. B., Adamowicz, P., Kurpeta, M., & Wojcieszak, J. (2023) · Forensic Science International · doi:10.1016/j.forsciint.2023.111775 · Cited by 55 · cited 4×
“This polysubstance use, often involving combinations with fentanyl, methamphetamine, amphetamine, or flualprazolam, further complicates clinical management and increases the risk of synergistic respiratory depression [7,12,27].”
InfluentialMu-Opioid Receptor Selective Superagonists Produce Prolonged Respiratory Depression
Malcolm, N. J., Palkovic, B., Sprague, D. J., Calkins, M. M., Lanham, J. K., Halberstadt, A. L., Stucke, A. G., & McCorvy, J. D. (2023) · iScience · doi:10.1016/j.isci.2023.107121 · Cited by 53
Glatfelter, G. C., Vandeputte, M. M., Chen, L., Walther, D., Tsai, M.-H. M., Shi, L., Stove, C. P., & Baumann, M. H. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06451-2 · Cited by 52 · cited 1×
“This extreme potency means that even minimal quantities can cause intoxications and deadly overdoses, exacerbating the ongoing opioid crisis in regions like North America, Europe, and Australia [10–12].”
United Nations Office on Drugs and Crime (2025) · World Drug Report · doi:10.18356/9789211594850 · Cited by 49
Shifting drug markets in North America - a global crisis in the making?
Meyer, M., Westenberg, J. N., Jang, K. L., Choi, F., Schreiter, S., Mathew, N., King, C., Lang, U. E., Vogel, M., & Krausz, R. M. (2023) · International Journal of Mental Health Systems · doi:10.1186/s13033-023-00601-x · Cited by 41
Cited by
The Nitazene Era: A Critical Turning Point in the Synthetic Opioid Crisis Beyond Fentanyl
Dow, L. F., Abisogun, A. A., Berida, T. I., Krishnan, S. C., Rathnayake, U., & Lindsley, C. W. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00696 · Cited by 2
Stability and turbulence in illegal drug markets
Kilmer, B. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2512078123 · Cited by 3
“…released United Nations Office on Drugs and Crime (UNODC) data show large increases in purity - adjusted heroin prices in Europe from 2022–2024 (43), suggesting this is not an idle fear—especially with increased men tions of nitazene (a synthetic opioid) seizures and overdoses in Europe (45, 46).”
Mestria, S., Odoardi, S., Valentini, V., Biosa, G., & Rossi, S. S. (2026) · Forensic Science International · doi:10.1016/j.forsciint.2026.113094 · Cited by 1
Rotolo, M. C., Graziano, S., BELARDI, G., Minutillo, A., Varı̀, M. R., & Marchei, E. (2026) · Biochimica Clinica · doi:10.23736/s0393-0564.26.00144-5 · Cited by 1
Maxwell, M. K., Anwar, A. I., Hasoon, J., & Kaye, A. D. (2026) · Current Pain and Headache Reports · doi:10.1007/s11916-026-01525-0
“It has been described as 1000-fold more potent than morphine is at the same receptor [23].”
Metadata
- Authors
- Pereira, J. R. P., Quintas, A., & Neng, N. R.
- Affiliations
- University of Lisbon (PT)
- Escola Superior de Saúde Egas Moniz (PT)
- Corresponding author
- Neng, Nuno R.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2025-09-26
- Volume
- 30
- Issue
- 19
- Pages
- 3890
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC12526229
- OpenAlex
- W4414546090
- Cited by
- 21
- References
- 64
- Citations by year
- 2026: 21
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- FCT (UIDB/00100/2020, UIDP/00100/2020, LA/P/0056/2020, 10.54499/UIDB/04585/2020)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Keywords
- nitazenes, synthetic opioids, etonitazene, isotonitazene, opioid overdose, respiratory depression, drug adulteration, counterfeit drugs, drug detection, clinical management, drug regulation, pharmacovigilance
- MeSH terms
- Analgesics, Opioid, Animals, Humans, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nitazenes: The Emergence of a Potent Synthetic Opioid Threat. https://app.cochat.ai/papers/10.3390/molecules30193890
- The paper
- Pereira, J. R. P., Quintas, A., & Neng, N. R. (2025). Nitazenes: The Emergence of a Potent Synthetic Opioid Threat. Molecules. https://doi.org/10.3390/molecules30193890
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.